May 21, 2013
/PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that
, CEO, will present at the 2
Annual Marcum LLP MicroCap Conference on
Thursday, May 30, 2013
New York City
at the Grand Hyatt Hotel. Mr. Riley is scheduled to present at
10:00 a.m. (Eastern Time)
A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the web at
. After the presentation, a replay will be archived and accessible for 30 days at the same website.
Mr. Riley, as well as Synthetic Biologics' CFO,
C. Evan Ballantyne
, will be available to participate in one-on-one meetings with investors and analysts who are registered to attend the conference. Please contact the Marcum conference representative
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of
infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and
infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at
To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your
iPhone and iPad
Android mobile device
SOURCE Synthetic Biologics, Inc.